137 related articles for article (PubMed ID: 10547983)
1. [Phase 1 clinical study of 123I-FP-CIT, a new radioligand for evaluating dopamine transporter with SPECT (I): Biodistribution and absorbed dose].
Takano K; Matsumura K; Watanabe Y; Yamada T; Kubo H; Naitou Y; Narita Y; Kuzuhara S; Takeda K
Kaku Igaku; 1999 Sep; 36(7):735-44. PubMed ID: 10547983
[TBL] [Abstract][Full Text] [Related]
2. Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters.
Booij J; Busemann Sokole E; Stabin MG; Janssen AG; de Bruin K; van Royen EA
Eur J Nucl Med; 1998 Jan; 25(1):24-30. PubMed ID: 9396871
[TBL] [Abstract][Full Text] [Related]
3. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.
Booij J; Andringa G; Rijks LJ; Vermeulen RJ; De Bruin K; Boer GJ; Janssen AG; Van Royen EA
Synapse; 1997 Nov; 27(3):183-90. PubMed ID: 9329154
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT.
Nikolaus S; Wirrwar A; Antke C; Arkian S; Schramm N; Müller HW; Larisch R
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):308-13. PubMed ID: 15791440
[TBL] [Abstract][Full Text] [Related]
5. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
6. [Metabolism of 123I-FP-CIT in humans].
Tanaka A; Okano K; Tamagami H; Matsumoto H; Tanifuji S; Yamamichi Y; Yoshimura H; Katoazuma M; Takano K; Matsumura K; Takeda K
Kaku Igaku; 1999 Sep; 36(7):745-51. PubMed ID: 10547984
[TBL] [Abstract][Full Text] [Related]
7. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
[TBL] [Abstract][Full Text] [Related]
8. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
9. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
10. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain.
Kuikka JT; Akerman K; Bergström KA; Karhu J; Hiltunen J; Haukka J; Heikkinen J; Tiihonen J; Wang S; Neumeyer JL
Eur J Nucl Med; 1995 Jul; 22(7):682-6. PubMed ID: 7498231
[TBL] [Abstract][Full Text] [Related]
11. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT.
Abi-Dargham A; Gandelman MS; DeErausquin GA; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Laruelle M; Charney DS; Hoffer PB; Neumeyer JL; Innis RB
J Nucl Med; 1996 Jul; 37(7):1129-33. PubMed ID: 8965183
[TBL] [Abstract][Full Text] [Related]
12. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain.
Kuikka JT; Bergström KA; Ahonen A; Hiltunen J; Haukka J; Länsimies E; Wang S; Neumeyer JL
Eur J Nucl Med; 1995 Apr; 22(4):356-60. PubMed ID: 7607268
[TBL] [Abstract][Full Text] [Related]
13. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
Booij J; Speelman JD; Horstink MW; Wolters EC
Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
[TBL] [Abstract][Full Text] [Related]
14. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers.
Lavalaye J; Booij J; Reneman L; Habraken JB; van Royen EA
Eur J Nucl Med; 2000 Jul; 27(7):867-9. PubMed ID: 10952500
[TBL] [Abstract][Full Text] [Related]
15. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
[TBL] [Abstract][Full Text] [Related]
16. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
[TBL] [Abstract][Full Text] [Related]
17. Human biodistribution and dosimetry of iodine-123-fluoroalkyl analogs of beta-CIT.
Abi-Dargham A; Innis RB; Wisniewski G; Baldwin RM; Neumeyer JL; Seibyl JP
Eur J Nucl Med; 1997 Nov; 24(11):1422-5. PubMed ID: 9371877
[TBL] [Abstract][Full Text] [Related]
18. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA
Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880
[TBL] [Abstract][Full Text] [Related]
19. [Striatal dopamine transporter levels in patients with REM sleep behavior disorder: assessment with 123I-FP-CIT SPECT].
Mossa EP; Niccoli Asabella A; Iuele F; Stabile Ianora AA; Giganti M; Rubini G
Recenti Prog Med; 2012 Nov; 103(11):500-4. PubMed ID: 23096739
[TBL] [Abstract][Full Text] [Related]
20. [Phase 1 clinical study of 123I-FP-CIT, a new radioligand for evaluating dopamine transporter by SPECT (II): Tracer kinetics in the brain].
Takano K; Matsumura K; Watanabe Y; Yamada T; Kubo H; Naitou Y; Narita Y; Kuzuhara S; Takeda K
Kaku Igaku; 1999 Dec; 36(9):1013-22. PubMed ID: 10659586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
